BMGF (Gates Foundation)
http://www.gatesfoundation.org/Media-Center/Press-Releases

.
MARCH 05, 2015
The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology
SEATTLE, WA, USA and TÜBINGEN, GERMANY (March 5, 2015) – The Bill & Melinda Gates Foundation and CureVac today announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform. In addition, CureVac’s longstanding investor dievini Hopp BioTech announced a commitment of $24 million (€21 million) of additional equity.